Treatment of hypertension by a new transdermal form of clonidine

We studied one or two adhesive systems per week of clonidine TTS (2.54 or 5.08 mg/week). The results showed a more marked antihypertensive action with these adhesive systems than with 0.15 or 0.30 mg/day of the oral form. The transdermal system was better tolerated systemically and local cutaneous reactions prevented its use in only one case in our series. Overall, the patients were satisfied with the treatment. In our opinion, the simplicity of administration of clonidine TTS should improve the long term patient compliance with antihypertensive treatment.